Research Shows Benefits of Eliquis Over Warfarin For Atrial Fibrillation Patients

While warfarin has long been a common treatment option for patients with atrial fibrillation new medications are coming to the market which provide different benefits than the original option.

Jack Lawrence, MD, Vice President, Cardiovascular Specialty Development and Development Lead for Apixaban at Bristol-Myers Squibb, and Christoph Koenen, Vice President, Cardiovascular, at Bristol-Myers discussed the development of the treatment option during the annual American Heart Association Scientific Sessions in Orlando.

With new treatment medications available, particularly when it comes to anticoagulants there is good news for patient care. That good news is expected to continue into the future.